Drug intelligence / Profile preview

bifidobacterium longum + lactobacillus reuteri

Development stage: Preclinical
Lead developer: BioGaia
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum + Lactobacillus reuteri is a probiotic combination of two specific bacterial species intended to support gut health. This combination is being clinically investigated for a range of health benefits by modulating the gut microbiome. Clinical trials have explored its use in reducing uremic toxins in patients with chronic kidney disease (CKD), alleviating anxiety and depression in postoperative colorectal cancer patients, and preventing Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) syndrome. The proposed mechanism involves the introduction of beneficial bacteria to the gut, which is believed to reduce harmful microbiota-derived toxins, decrease systemic inflammation, and positively influence the gut-brain and gut-kidney axes. The specific strains used in trials include Bifidobacterium longum BB536 and Lactobacillus reuteri DSM17938.

Other names: Bifidobacterium longum and Lactobacillus reuteri combination

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on bifidobacterium longum + lactobacillus reuteri.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum + lactobacillus reuteri.

Explore the full profile